{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+-+intravenous", "query": { "intervention": "normal saline - intravenous" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1057, "total_pages": 106, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=normal+saline+-+intravenous&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-17T02:23:11.057Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03207243", "title": "Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "GSK3772847", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluticasone propionate/salmeterol", "type": "DRUG" }, { "name": "Fluticasone propionate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 165, "start_date": "2017-09-14", "completion_date": "2019-05-15", "has_results": true, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Scottsboro, Alabama • Bakersfield, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03207243" }, { "nct_id": "NCT04400058", "title": "Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Covid-19" ], "interventions": [ { "name": "Octagam 10%", "type": "BIOLOGICAL" }, { "name": "Saline Solution", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Octapharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 207, "start_date": "2020-06-01", "completion_date": "2022-02-01", "has_results": true, "last_update_posted_date": "2024-01-18", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 15, "location_summary": "Sheffield, Alabama • Loma Linda, California • Newport Beach, California + 11 more", "locations": [ { "city": "Sheffield", "state": "Alabama" }, { "city": "Loma Linda", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04400058" }, { "nct_id": "NCT01691690", "title": "Analgesic Effect of IV Acetaminophen in Tonsillectomies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenotonsillitis", "Tonsillitis" ], "interventions": [ { "name": "Acetaminophen (paracetamol)", "type": "DRUG" }, { "name": "Normal Saline Flush", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Sevoflurane", "type": "DRUG" }, { "name": "Nitrous Oxide/Oxygen", "type": "DRUG" }, { "name": "Propofol", "type": "DRUG" }, { "name": "Morphine", "type": "DRUG" }, { "name": "Ondansetron", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "9 Years", "sex": "ALL", "summary": "2 Years to 9 Years" }, "enrollment_count": 250, "start_date": "2012-10", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2017-04-06", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01691690" }, { "nct_id": "NCT03834506", "title": "Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1030, "start_date": "2019-05-02", "completion_date": "2023-07-18", "has_results": true, "last_update_posted_date": "2025-07-18", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 28, "location_summary": "Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834506" }, { "nct_id": "NCT03222492", "title": "Brentuximab Vedotin for Systemic Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis", "Scleroderma", "dcSSc" ], "interventions": [ { "name": "Brentuximab Vedotin", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 17, "start_date": "2017-09-20", "completion_date": "2023-04-10", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 8, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Ann Arbor, Michigan + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03222492" }, { "nct_id": "NCT01951716", "title": "Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Does the Vagus Nerve Mediate the Effects of Xenin-25" ], "interventions": [ { "name": "Graded Glucose Infusion with Placebo", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP Alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with xenin-25 alone", "type": "DRUG" }, { "name": "Graded Glucose Infusion with GIP plus xenin-25", "type": "DRUG" }, { "name": "Meal Tolerance Test with Placebo", "type": "DRUG" }, { "name": "Meal Tolerance Test with xenin-25", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 0, "start_date": "2013-01", "completion_date": "2018-07", "has_results": false, "last_update_posted_date": "2018-04-26", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951716" }, { "nct_id": "NCT02525471", "title": "A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "ALS" ], "interventions": [ { "name": "RNS60", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sabrina Paganoni, M.D.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2015-10", "completion_date": "2017-10-18", "has_results": true, "last_update_posted_date": "2021-05-28", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02525471" }, { "nct_id": "NCT01375634", "title": "Nasogastric Tube Insertion Using Midazolam in the Emergency Department", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Intubation; Difficult" ], "interventions": [ { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2011-05", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2013-07-22", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 1, "location_summary": "Burlington, Vermont", "locations": [ { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375634" }, { "nct_id": "NCT00350298", "title": "Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Infections" ], "interventions": [ { "name": "GS-CDA1/MDX-1388", "type": "BIOLOGICAL" }, { "name": "normal saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MassBiologics", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2006-07-20", "completion_date": "2008-06-25", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 22, "location_summary": "Los Angeles, California • Oakland, California • Newark, Delaware + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350298" }, { "nct_id": "NCT03446599", "title": "Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vasoplegia", "Hypotension", "Coronary Artery Disease", "Cardiac Valve Disease" ], "interventions": [ { "name": "Hydroxocobalamin", "type": "DRUG" }, { "name": "Methylene Blue", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-17T02:23:11.057Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446599" } ] }